Betaxolol in patients with glaucoma and asthma

E. M. Van Buskirk, Robert N. Weinreb, David P. Berry, Jacqueline S. Lustgarten, Steven M. Podos, Margaret M. Drake

Research output: Contribution to journalArticlepeer-review

55 Scopus citations


We evaluated the use of topically administered betaxolol, a cardioselective beta-adrenergic blocking agent, in 11 patients (eight women and three men, 40 to 81 years old) who had asthma and severe glaucoma with increased intraocular pressure despite maximally tolerated medical therapy. In each of these patients, timolol was either contraindicated or had previously led to development of pulmonary symptoms or complications. Before betaxolol, mean forced expiratory volumes in one second were 66% in the men and 80% in the women of reported normal values in age- and height-matched groups. Betaxolol was then topically administered twice daily. All patients continued to administer betaxolol without exacerbation of pulmonary symptoms and without deterioration in measured pulmonary function tests. Betaxolol further reduced intraocular pressure by a mean of 18% (4 mm Hg) when added to the patients' otherwise maximal regimen.

Original languageEnglish
Pages (from-to)531-534
Number of pages4
JournalAmerican Journal of Ophthalmology
Issue number5
StatePublished - 15 May 1986


Dive into the research topics of 'Betaxolol in patients with glaucoma and asthma'. Together they form a unique fingerprint.

Cite this